| Name | YS-49 |
| Description | YS-49 is an activator of PI3K/Akt (a downstream target of RhoA). |
| In vitro | In RAVSMC and RAW 264.7 cells, YS-49 (1-100?μM; 18 hours; ) concentration-dependently inhibits the accumulation of nitrite in both RAVSMC and RAW 264.7 exposed to lipopolysaccharide (LPS) plus INF-γ, with IC50 values of 22 μM and 30?μM, respectively[2].At the transcriptional level, YS-49 (10-100?μM; 18 hours; RAVSMC and RAW 264.7 cells) suppresses iNOS gene expression induced by LPS and/or cytokines in RAVSMC and RAW 264.7 cells [2]. |
| In vivo | In male Sprague Dawley rats,YS-49 (5mg/kg; intraperitoneal injection; 8 hours) treatment significantly reduces serum NOx levels in LPS-treated rats, the NOx levels reduce from 86 μM to 34 μM[2]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 10 mg/mL (25.89 mM), Sonication and heating to 60℃ are recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (10.36 mM), Sonication is recommended. DMSO : 250 mg/mL (647.2 mM), Sonication is recommended.
|
| Keywords | β-adrenoceptor | YS-49 | YS49 | YS 49 | Protein kinase B | PKB | PI3K | Phosphoinositide 3-kinase | Inhibitor | inhibit | Beta Receptor | Angiotensin Receptor | Akt | AdrenergicReceptor | Adrenergic Receptor |
| Inhibitors Related | Aceglutamide | Losartan potassium | Musk ketone | Stearamide | Bisphenol A | Myricetin | Hyaluronic acid | Ethyl linoleate | Methyl eugenol | 2,3-Butanediol | Diisononyl phthalate | Captopril |
| Related Compound Libraries | Glycolysis Compound Library | Glycometabolism Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Alkaloid Natural Product Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Neuroprotective Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |